|
Brook Byers has been closely involved with more than forty new technology based ventures, including being founding President, and later Chairman, of four biotechnology companies which went on to be public companies with an aggregate market value over $8 billion. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. He is currently on the Board of Directors of CardioDx, GenomicHealth, OptiMedica, Pacific Biosciences, Inc. and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (Chairman), Hybritech (Chairman), Genprobe, Nanogen, and others. He is currently a Board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the New Schools Foundation, Stanford's Bio-X Advisory Council, the Stanford Eye Council and TechNet. Mr. Byers graduated in Electrical Engineering from Georgia Tech and received an M.B.A. from Stanford. | 